STOCK TITAN

[8-K] NovaBay Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

NovaBay Pharmaceuticals filed a corporate designation for a new preferred stock class. The company reported that it filed a Certificate of Designation for its Series E Non-Voting Convertible Preferred Stock with the Delaware Secretary of State on October 16, 2025.

The filing furnishes this Certificate of Designation as Exhibit 3.1. NovaBay’s common stock trades on NYSE American under the symbol NBY.

NovaBay Pharmaceuticals ha presentato una designazione societaria per una nuova classe di azioni privilegiate. L'azienda ha comunicato di aver depositato una Certificazione di Designazione per la sua Serie E di Azioni Privilegiate Convertibili senza diritto di voto presso il Segretario di Stato del Delaware il 16 ottobre 2025.

La presentazione fornisce questa Certificazione di Designazione come Allegato 3.1. Le azioni ordinarie di NovaBay sono negoziate sul NYSE American con il simbolo NBY.

NovaBay Pharmaceuticals presentó una designación corporativa para una nueva clase de acciones preferentes. La compañía informó que presentó una Certificación de Designación para su Serie E de Acciones Preferentes Convertibles Sin Derecho a Voto ante el Secretario de Estado de Delaware el 16 de octubre de 2025.

La presentación adjunta esta Certificación de Designación como Anexo 3.1. Las acciones ordinarias de NovaBay cotizan en NYSE American bajo el símbolo NBY.

노바베이 파마슈티컬스가 새로운 우선주 계열에 대한 기업 지정서를 제출했습니다. 이 회사는 델라웨어 주 무역상무장관에게 2025년 10월 16일 시리즈 E 무의결 전환가능 우선주에 대한 설계 인증서를 제출했다고 보고했습니다.

이 제출서는 이 설계 인증서를 부속서 3.1로 제공합니다. 노바베이의 보통주는 NYSE American에서 NBY 기호로 거래됩니다.

NovaBay Pharmaceuticals a déposé une désignation d'entreprise pour une nouvelle catégorie d'actions privilégiées. La société a indiqué avoir déposé un Certificat de Désignation pour sa Série E d'Actions privilégiées Convertibles sans droit de vote auprès du Secrétaire d'État du Delaware le 16 octobre 2025.

Le dépôt joint ce Certificat de Désignation en tant que Pièce 3.1. Les actions ordinaires de NovaBay se négocient sur le NYSE American sous le symbole NBY.

NovaBay Pharmaceuticals hat eine unternehmensbezogene Festlegung für eine neue Klasse von Vorzugsaktien eingereicht. Das Unternehmen berichtete, dass es am 16. Oktober 2025 eine Certificate of Designation für seine Serie E Nicht-Stimmrechts Convertible Preferred Stock beim Secretary of State von Delaware eingereicht hat.

Die Einreichung fügt dieses Certificate of Designation als Exhibit 3.1 bei. NovaBays Stammaktien werden an der NYSE American unter dem Symbol NBY gehandelt.

قدمت شركة NovaBay Pharmaceuticals تعيينًا كشركة لفئة جديدة من الأسهم الممتازة. أفادت الشركة بأنها قدمت شهادة Designation لتصنيف إصدارها من الأسهم الممتازة القابلة للتحويل من الفئة E بدون حق التصويت لدى أمين سجل Delaware في 16 أكتوبر 2025.

توفر هذه الشهادة Designation كمرفق 3.1. تتداول أسهم NovaBay العادية في NYSE American تحت الرمز NBY.

NovaBay Pharmaceuticals 已为一种新型优先股类别提交了公司指定。 公司报告称,于 2025 年 10 月 16 日向特拉华州州务卿提交了其 Series E Non-Voting Convertible Preferred Stock 的指定证书。

该提交将此指定证书作为附件 3.1 提供。NovaBay 的普通股在 NYSE American 交易,代码为 NBY。

Positive
  • None.
Negative
  • None.

NovaBay Pharmaceuticals ha presentato una designazione societaria per una nuova classe di azioni privilegiate. L'azienda ha comunicato di aver depositato una Certificazione di Designazione per la sua Serie E di Azioni Privilegiate Convertibili senza diritto di voto presso il Segretario di Stato del Delaware il 16 ottobre 2025.

La presentazione fornisce questa Certificazione di Designazione come Allegato 3.1. Le azioni ordinarie di NovaBay sono negoziate sul NYSE American con il simbolo NBY.

NovaBay Pharmaceuticals presentó una designación corporativa para una nueva clase de acciones preferentes. La compañía informó que presentó una Certificación de Designación para su Serie E de Acciones Preferentes Convertibles Sin Derecho a Voto ante el Secretario de Estado de Delaware el 16 de octubre de 2025.

La presentación adjunta esta Certificación de Designación como Anexo 3.1. Las acciones ordinarias de NovaBay cotizan en NYSE American bajo el símbolo NBY.

노바베이 파마슈티컬스가 새로운 우선주 계열에 대한 기업 지정서를 제출했습니다. 이 회사는 델라웨어 주 무역상무장관에게 2025년 10월 16일 시리즈 E 무의결 전환가능 우선주에 대한 설계 인증서를 제출했다고 보고했습니다.

이 제출서는 이 설계 인증서를 부속서 3.1로 제공합니다. 노바베이의 보통주는 NYSE American에서 NBY 기호로 거래됩니다.

NovaBay Pharmaceuticals a déposé une désignation d'entreprise pour une nouvelle catégorie d'actions privilégiées. La société a indiqué avoir déposé un Certificat de Désignation pour sa Série E d'Actions privilégiées Convertibles sans droit de vote auprès du Secrétaire d'État du Delaware le 16 octobre 2025.

Le dépôt joint ce Certificat de Désignation en tant que Pièce 3.1. Les actions ordinaires de NovaBay se négocient sur le NYSE American sous le symbole NBY.

NovaBay Pharmaceuticals hat eine unternehmensbezogene Festlegung für eine neue Klasse von Vorzugsaktien eingereicht. Das Unternehmen berichtete, dass es am 16. Oktober 2025 eine Certificate of Designation für seine Serie E Nicht-Stimmrechts Convertible Preferred Stock beim Secretary of State von Delaware eingereicht hat.

Die Einreichung fügt dieses Certificate of Designation als Exhibit 3.1 bei. NovaBays Stammaktien werden an der NYSE American unter dem Symbol NBY gehandelt.

false 0001389545 0001389545 2025-10-16 2025-10-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 16, 2025

 

NovaBay Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-33678   68-0454536

(State or other jurisdiction
of incorporation)

  (Commission
File Number)
 

(IRS Employer

Identification No.)

 

2000 Powell Street, Suite 1150, Emeryville, CA 94608

(Address of principal executive offices and zip code)

 

(510) 899-8800

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which registered

Common Stock, par value $0.01 per share   NBY   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Information.

 

As previously disclosed in the Current Report on Form 8-K filed by NovaBay Pharmaceuticals, Inc. (the “Company”) on October 20, 2025, the Company filed the certificate of designation of preferences, rights and limitations of Series E Non-Voting Convertible Preferred Stock, par value $0.01 per share (the “Certificate of Designation for the Series E Preferred Stock”) with the Delaware Secretary of State on October 16, 2025. The Certificate of Designation for the Series E Preferred Stock is filed as Exhibit 3.1 to this Current Report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
3.1   Certificate of Designation of Preferences, Rights and Limitations of Series E Non-Voting Convertible Preferred Stock
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: October 22, 2025 NovaBay Pharmaceuticals, Inc.
     
  By: /s/ Tommy Law
    Name: Tommy Law
    Title: Chief Financial Officer

 

2

FAQ

What did NBY announce in this 8-K?

NovaBay reported filing a Certificate of Designation for its Series E Non-Voting Convertible Preferred Stock with the Delaware Secretary of State.

When was the Certificate of Designation filed?

The certificate was filed on October 16, 2025.

Which exhibit includes the new designation details?

The Certificate of Designation is furnished as Exhibit 3.1.

What exchange and symbol does NovaBay trade under?

NovaBay’s common stock trades on NYSE American under the symbol NBY.

What security class is covered by the certificate?

It covers Series E Non-Voting Convertible Preferred Stock.

Under which item was this disclosed?

The update appears under Item 8.01 (Other Information).
Novabay Pharma

NYSE:NBY

NBY Rankings

NBY Latest News

NBY Latest SEC Filings

NBY Stock Data

6.97M
6.01M
0.02%
21.27%
31.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
EMERYVILLE